It has been proposed that adoptive immunotherapy, for the treatment of relapsed AML, with cytotoxic T lymphocytes which show a relative specificity for the leukemic cells may have the advantage of maximizing the beneficial anti-leukemic effect whilst minimizing the probability of graft-versus-host disease. In this study we differentiated peripheral blood AML cells in vitro into functional dendritic cells (DCs), as demonstrated by cell morphology, immunophenotype and functional activity, in the presence of GM-CSF, IL-4, TNF-␣ and FLT3 ligand. Such DCs could be differentiated from 77% of AML patients, irrespective of their FAB classification and clinical status and, in all cases tested, the DCs were shown to derive from the leukemic clone by FISH analysis. Importantly, from Ͼ60% of AML patients, autologous T lymphocytes stimulated with these in vitro generated leukemic DCs displayed specific cytotoxic activity against AML blasts but low reactivity against autologous non-leukemic targets and HLA-matched normal PBMNCs therefore suggesting that the CTLs were AML-specific. The use of FLT3 ligand in our system resulted in a significantly higher number of leukemic DCs as compared to cultures from which FLT3 ligand was omitted which is obviously advantageous if large numbers of specific CTLs are to be generated in the shortest possible time. Leukemia (2001) 15, 246-255. 
Introduction
Over the past decade, the prognosis of patients with acute myeloid leukemia (AML) has improved as a result of refinements in the diagnosis of the various subtypes and advances in therapeutic approaches. However, despite these improvements, the overall survival rate amongst patients who are less then 65 years of age is still only 40%. 1 Allogeneic bone marrow transplantation (allo-BMT) from an HLA-matched sibling is now a well established treatment option for 20-30% of younger AML patients (Ͻ45 years old) with 60-70% of these patients surviving more then 5 years. The efficacy of allogeneic transplantation may result not only from the high-dose myeloablative pre-transplant conditioning, but also from an allogeneic immune mechanism, known as the graft-versus-leukemia effect (GVL). 2, 3 There is now considerable evidence that this GVL effect has a pivotal antitumoral role since a higher rate of relapse occurs after syngeneic BMT as compared to allo-BMT, 4 T cell depletion of the graft significantly increases the rate of leukemic relapse 5 and donor lymphocyte transfusion (DLT) can re-induce a stable hematologic remission in 25% of AML patients with relapsed disease. 6, 7 The use of DLT, however, is not without risk, with a significant number of patients developing graft-versus-host disease (GVHD) or bone marrow hypoplasia. Therefore, it has been proposed that adoptive immunotherapy with cytotoxic T lymphocytes (CTL) which show a relative specificity for the leukemic cells may have the advantage of maximizing the anti-leukemia effect whilst minimizing the probability of GVHD.
The induction of a primary CTL response requires not only efficient antigen presentation through the MHC complex, but also co-stimulatory signals delivered by APCs, in particular via the CD28/B7 pathway, in order to induce effective T cell immunity as opposed to alloantigen-specific anergy. [8] [9] [10] Native AML blasts, although expressing MHC class I and II molecules on their surface, are generally devoid of the critical co-stimulatory molecules, CD80 and CD86, hence their ability to induce an effective immune response is impaired.
One way in which these deficiencies may be corrected is to differentiate the AML blasts into antigen-presenting cells (APCs) such as dendritic cells, using combinations of cytokines. Dendritic cells (DC) are highly efficient APCs which have the ability to stimulate the generation of helper T cell responses and cytotoxic cells from naive T cells in vitro. 11 Recent studies have shown that DCs generated from AML patients can be derived from the malignant clone and that, in some cases, these malignant DCs can be used to induce a primary AML-directed cytotoxic immune response in vitro. [12] [13] [14] A variety of cytokine cocktails have been used to differentiate AML blasts, derived either from the peripheral blood or from the bone marrow, into DCs, including GM-CSF, IL-4, TNFalpha, IL-6, SCF and soluble CD 40 ligand.
In this study we used the combination of GM-CSF, IL-4, TNF-alpha with or without additional FLT3 ligand. The reasons for choosing FLT3 ligand were two-fold; firstly, regardless of the FAB subtype, the vast majority of AML blasts are FLT3-positive and in vitro growth assays have shown that FLT3 ligand causes a proliferative response in a high percentage of AML cases. [15] [16] [17] Secondly, the GM-CSF plus TNF-alphadependent in vitro generation of DCs from CD34 + cells is enhanced by FLT3 ligand. 18 Considering that the majority of AML blasts are CD34 + , we reasoned that FLT3 ligand may be useful in generating large numbers of leukemic DCs which could subsequently be used to stimulate primary AML-specific CTL responses in vitro.
Materials and methods

Samples and culture of dendritic cells
After informed consent, peripheral blood mononuclear cells (PBMNCs) were obtained from heparinized peripheral blood (PBL) of patients with AML by Ficoll-Hypaque (Lymphoprep; Nycomed Pharma, Oslo, Norway) density gradient centrifugation. The mononuclear cell fraction was washed twice with phosphate-buffered saline (PBS) and resuspended in complete
Quantitation of DC yield
After 14 days in culture, the total number of DC-like cells was counted using a hemocytometer and viability was assessed using trypan blue exclusion. Only large cells of irregular morphology with veiled processes and cytoplasmic projections were counted as positive. Using flow cytometry, cells which displayed the typical scatter of a dendritic cell were gated and the total percentage of DCs in the gate counted. Cells cultured in the presence or absence of FTL3 ligand were compared.
Enrichment of CD83
+ dendritic cells
For FISH analysis, DCs were enriched using an anti-CD83 antibody and immunomagnetic separation according to the manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). Briefly, AML cells which had been cultured for 14 days in the presence of FLT3 ligand, GM-CSF, IL-4 and TNF-alpha, were stained with a PE-conjugated mouse-antihuman CD83 antibody. In a second step, the labelled cells were incubated with anti-PE immunomagnetic beads for 15 min at 12°C. Using a magnetic separation column, CD83 + DCs were positively selected. H-thymidine (Amersham Life Science, Buckinghamshire, UK) was added to each well and incubation was continued for an additional 18 h. Cells were collected on to UniFilter plates (Canberra, CT, USA) using a FilterMate Cell Harvester (Canberra) and thymidine uptake was quantitated by liquid scintillation counting.
Phenotypic analysis
Phenotypic analysis of the proliferating T cells in the MLR was analyzed by flow cytometry using mAbs against CD3, CD4, CD8 and CD56 (Pharmingen). The samples were analyzed using a FACSCalibur flow cytometer and CellQuest software (Becton Dickinson, Mountain View, CA, USA).
Soluble antigen-presentation assay
DCs from each cytokine combination or freshly thawed AML cells were suspended in complete media containing 20 mg/ml recombinant tetanus toxin fragment C (Chiron Behring, Marburg, Germany) or complete medium alone and incubated overnight at 37°C. The cells were then irradiated (3000 cGy), washed with RPMI 1640, counted and placed in triplicate wells of a 96-well plate at 200-5000 cells per well. Purified autologous T lymphocytes, prepared as above, were added to the DCs at 10 5 cells/well in a final volume of 200 l complete medium, and incubated for 5 days. 1 mCi of methyl-3 H-thymidine was added to each well and incubation was continued for an additional 18 h. Thymidine uptake was quantitated as described above.
Expansion of T cells from AML patients
PBMNCs from AML patients were suspended at a concentration of 1 × 10 6 cells/ml and cultured in complete RPMI 1640 media containing 1000U/ml IFN-␣ for 24 h. The cells were then washed and resuspended in media containing 5 g/ml Conavalin A (Sigma, Deisenhofen, Germany) and 500 U/ml IL-2 (Chiron Therapeutics, Emeryville, CA, USA). Nonadherent cells were resuspended in fresh medium containing 
Figure 1
The total number of viable DCs grown either in the presence of FLT3 ligand (+FLT3L) or in the absence of FLT3L (−FLT3L) was assessed by light microscopy and trypan blue exclusion. From 11 AML patients (n = 55 separate data points), the total number of DCs was assessed after 14 days in culture. The dashed horizontal line (+FLT3L) and the solid horizontal line (−FLT3L) represent the mean number of DCs in each of the cultures.
IL-2 every 3-4 days. On day 7, these T cells were used as autologous non-leukemic targets in chromium release assays.
Leukemia-specific CTL lines
Leukemia-specific CTL lines were activated from the peripheral blood of AML patients by coculturing 2 × 10 6 PBMNCs per well of a 24-well plate, with 5 × 10 4 dendritic cells (generated with GM-CSF, IL-4, TNF-alpha and FLT3 ligand as described) that had been irradiated with 40 Gy from a cesium source. After 10 days, the cells were harvested, subcultured in 24-well plates at 5 × 10 5 per well and restimulated with 1.25 × 10 5 irradiated DCs per well. This restimulation was continued every 7 days and after day +17, hIL2 (20 U/ml; Chiron Therapeutics) was added to the cultures three times per week. After 3-4 weeks in culture, the antileukemic activity of the induced CTL was assayed.
Cytotoxicity assays
The cytotoxicity of each CTL line was analyzed in a standard 4-h chromium-51 release assay using effector:target ratios of 40:1, 20:1, 10:1 and 5:1. Target cells included AML blasts from the patient at the time of diagnosis, patient T cell blasts (non-leukemic in origin), HLA-identical donor PBMNCs, HLAmismatched donor PBMNCs and the T cell line HSB-2, which is sensitive to killing by lymphokine-activated killer cells. To determine whether cytolysis was restricted by HLA class I or class II, target cells were preincubated for 30 min with 20 g/ml of W6/32 (Dako), a monoclonal antibody that recognizes a monomorphic HLA class I determinant or CR3/43 (Dako), which recognizes HLA-DR, -DP and -DQ and blocks HLA class II-restricted killing.
Results were expressed as % of specific lysis according to the following formula: experimental release − spontaneous release maximum release − spontaneous release × 100
Experimental release represents c.p.m. released from the target cells incubated with the effector cells; spontaneous release is that from target cells incubated in medium alone and maximum release is c.p.m. released from target cells after incubation with 2% Triton X-100 (Sigma).
Immunophenotyping
For cell-surface phenotyping, the CTLs were incubated with combinations of FITC or PE-conjugated monoclonal antibodies to CD3, CD4, CD8, CD56, CD16, CD19, HLA-DR, TCR-␣␤ or TCR-␥␦. Cells were analyzed on a FACScan flow cytometer.
Statistical analysis
To assess statistical significance between the two cytokine groups, the Student's t-test was used in most cases.
Results
Not all of the studies shown could be performed on every AML sample as only limited material was available.
Generation of dendritic cells in vitro
Peripheral blood mononuclear cells from 22 AML patients with a variety of FAB subtypes (Table 1) , clinical histories and cytogenetics, were cultured with either GM-CSF (800 U/ml), IL-4 (500 U/ml), and TNF-alpha (200 U/ml) or with GM-CSF (800 U/ml), IL-4 (500 U/ml), TNF-alpha (200 U/ml) and FLT3 ligand (200 U/ml). After 14 days in culture, the mean number of cells exhibiting typical DC morphology was different between the two cytokine groups as assessed by both light microscopy counting and FACS analysis (Figure 1 ). The total number of cells displaying typical DC morphology was sig- nificantly higher in the cultures containing FLT3 ligand as compared to cells grown in the absence of this cytokine (P Ͻ 0.003 using n = 55 data points) although the range was wide in both groups. In the presence of FLT3 ligand the total DC number ranged from 0.18 to 6.6 × 10 6 per ml (mean 3.05 ± 1.88 × 10 6 /ml) after 14 days in culture, as compared to DCs generated in the absence of FLT3 ligand which ranged in number from 0 to 3.8 × 10 6 per ml (mean 1.94 ± 1.2 × 10 6 /ml). On FACS analysis, gating on the DC population, in the absence of FLT3 ligand, 30.6 ± 15.6% of the cells displayed large-cell bodies, lobular nuclei and numerous fine, motile cytoplasmic projections whilst 39.2 ± 15.6% of cells grown in the presence of FLT3 ligand displayed similar morphology (P Ͻ 0.004, n = 55 data points from 22 AML patients) as shown in Figure 2b . There was no correlation between the starting AML blast (CD34 + ) cell count and the final percentage of cells expressing a DC-like morphology. The viability and morphology of the DCs from both cytokine groups could be maintained for more than 21 days in culture provided that they were fed every 4-5 days with fresh media and cytokines. Morphologically, there were no significant changes observed in either group of DCs after day 10 in culture.
In 5/22 (22.7%) AML patients, it was not possible to generate DCs from their peripheral blood using either cytokine combination. From three of these patients the blast cells died in culture after 2-3 days despite the cytokine cocktail used. The cells from the other two patients maintained their viability in culture for up to 14 days but did not morphologically or phenotypically resemble DCs. Although other cytokine combinations were not tested, the level of IL-10 in the serum of these five patients was assessed by ELISA but was undetectable (data not shown). Two of the patients from whom DCs could not be grown had AML M2 whilst the other three had AML M4 and their blast count ranged from 50% to 90%, in addition, all of the patients had relapsed more than once with two of them having already received an allogeneic BMT at the time they donated blood for this study. However, from other patients with similar clinical histories and FAB classifications etc, it was possible to generate DCs which were functionally capable of stimulating an AML-specific CTL response in vitro.
Demonstration that the DCs cultured in the presence of FLT3 ligand were of leukemic origin
In order to determine whether the cultured DCs from the FLT3 ligand-containing group originated from the malignant clone, FISH of interphase nuclei was performed. Cells from patient 16, with inverse 16, were cultured in the presence of FLT3 ligand for 14 days. The DCs were then enriched using CD83 magnetic beads and analyzed by interphase FISH using a dual-color probe for the CBF␤ gene rearrangement to detect the inversion 16. In the abnormal CBF␤ allele, two separate signals, a green one (region 16p13) and a red one (region 16q22) are seen ( Figure 3) . The normal CBF␤ allele shows a red-green fusion signal. At least 100 interphase nuclei were counted and Ͼ95% of the CD83 + DCs expressed inverse 16. FISH analysis of the DCs generated from another AML patient with trisomy 13 was also performed (data not shown) and, in this case, Ͼ80% of the DCs were positive for the chromosomal abberation.
Phenotypic analysis of the DCs
The initiating population of AML peripheral blood cells was heterogeneous, containing CD14 + , CD34
+ and CD56 + cells. In our culture system, the DCs were derived from both the CD14 + and the CD34 + cells. The effects of both cytokine combinations on the immunophenotype of the starting cell population was evaluated by flow cytometry after 14 days. In addition, freshly thawed AML blasts were stained with the same panel of fluorescent monoclonal anti-
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Figure 5
DCs generated from AML cells either in the presence or absence of FLT3 ligand are active in the allogeneic MLR assay. After 14 days in culture, varying numbers of DCs were added in triplicate walls containing 10 5 purified allogeneic T lymphocytes in complete medium. After 5 days of coculture, 3 H-thymidine was added for 18 h and the cells analyzed for thymidine uptake. The results represent the mean and standard deviation of data obtained from eight experiments.
Figure 6
DCs grown from AML cells either in the presence or absence of FLT3 ligand take up and present exogenous antigen. After 14 days in culture, DCs were cultured overnight in complete medium containing TT. The DCs were added in varying numbers to triplicate wells containing 10 5 purified T lymphocytes. After 5 days of coculture, 3 H-thymidine was added for 18 h and the cells analyzed for thymidine uptake. The results represent the mean and standard deviation of data obtained from eight experiments. bodies. From 15 AML patients, important phenotypic differences between DCs generated in the absence or presence of FLT3 ligand were observed. As illustrated in Figure 4a , which is the mean data from 15 AML patients, DCs generated in the presence of FLT3 ligand showed significantly higher levels of expression of HLA-ABC (P Ͻ 0.001), CD40 (P Ͻ 0.001) and the DC-specific marker CD83 (P Ͻ 0.001) as compared to DCs grown without FLT3 ligand. Both groups of DCs showed similar levels of expression of HLA-DR, CD80, CD86, CD1a and CD33. As compared to the freshly thawed AML blasts, which showed no or 5% expression of CD40, CD80, CD86, (a) Cytotoxicity of DC-stimulated T cells. DCs cultured in GM-CSF, IL-4, TNF-␣ plus or minus FLT3L were cocultured with autologous PBMNCs as described in Materials and methods. The CTL lines were examined for their cytotoxic activity against autologous leukemic blasts, autologous T cells which did not derive from the leukemic clone, allogeneic PBMNCs and HSB-2. Data points were calculated using the mean of triplicate cultures and the results represent the mean and standard deviation obtained from five AML patients. (b) To determine whether leukemia-specific lysis was restricted by HLA class I or class II, target cells were pre-incubated for 30 min with W6/32, a monoclonal antibody that recognizes HLA class I, or CR3/43, which recognizes HLA-DR, DP and DQ and blocks HLA class II-restricted killing. At an E:T ratio of 40:1, lysis of AML CD34 + blasts was blocked predominantly by W6/32 indicating that the majority of the killing was mediated by CD8 + T cells. There was minimal inhibition with the CR3/43 antibody. Data points were calculated using the mean of triplicate cultures and the results represent the mean and standard deviation obtained from five AML patients using CTL lines generated in the presence of FLT3L.
CD83 and CD1a, the DCs in both cytokine groups showed significantly higher levels of expression of CD40, CD80, CD86, CD83 and CD1a (all P Ͻ 0.001) whilst the level of expression of HLA-ABC (P Ͻ 0.05) and CD34 (P Ͻ 0.001) was significantly decreased and the level of HLA-DR and CD33 was not significantly changed. 
Functional properties of DCs generated from AML patients
The immunostimulatory capacity of the DCs from both cytokine groups, as well as freshly thawed blasts, was assessed by allogeneic MLR assays. Various numbers of irradiated +FLT3 ligand, −FLT3 ligand DCs or fresh AML cells were co-cultured with 1 × 10 5 purified allogeneic T cells. Proliferation of the responder T cells was assessed at the end of 5 days by measuring the incorporation of 3 H-thymidine added for the final 18 h of culture. As shown in Figure 5 the DCs from both cytokine groups (±FLT3 ligand) were potent stimulators of T cells, whereas freshly thawed AML cells had a much poorer capacity to stimulate the T cells at all of the T:DC ratios tested (P Ͻ 0.0001) Despite the phenotypic differences observed in the DCs (described above) between the two cytokine groups (plus or minus FLT3 ligand) there was no significant difference in their capacity to stimulate allogeneic T cells. Figure 5 represents the mean results obtained from eight different AML patients each measured once in triplicate.
Phenotypically, in the +FLT3L cultures the proliferating T cells were CD4 (52.8 ± 27.4%) with 26.4 ± 16.9% being CD8 and in the −FLT3L cultures there were 60 ± 8.5% CD4 + cells and 34.5 ± 13% CD8 + T cells with no significant differences being observed between these two DC groups.
DCs are potent presenters of exogenous antigens
Leukemic DCs, from eight AML patients (each measured once in triplicate), grown in the presence or absence of FLT3 ligand were compared with freshly thawed AML cells for their capacity to uptake, process and present tetanus toxoid to autologous, purified T lymphocytes. As shown in Figure 6 , at all of the T:DC ratios tested, both groups of leukemic DCs stimulated T cells significantly better than fresh blasts (P Ͻ 0.0001), although there was no significant difference between FLT3L+ or FLT3L− DCs as assessed by a Student's t-test.
Phenotypic analysis showed that DCs generated in the presence of FLT3 ligand stimulated CD4 T cells (48.4 ± 23.7%) as well as CD8 T cells (36.5 ± 15.1%). DCs generated in the absence of FLT3L stimulated 47.5 ± 22.4% CD4 cells and 32 ± 15.6% CD8 cells and there were no significant differences observed between the two groups (data not shown).
Cytotoxicity of DC-stimulated T cells
For induction of a specific CTL response against AML cells, DCs grown in GM-CSF, IL-4, TNF-alpha plus or minus FLT3 ligand were used as stimulators and autologous PBMNCs were used as responder cells. After three weekly stimulations, from 75% of AML patients, it was possible to generate T cell lines which specifically recognized CD34
+ AML blasts and showed minimal reactivity against other MHC-matched or HLA-mis-253 matched targets. Figure 7a shows the mean results obtained from five AML patients and represents the cytotoxicity against CD34 + AML blasts, PHA-stimulated autologous T cells which did not derive from the leukemic clone, HLA-matched PBMNCs from a healthy donor HLA-mismatched PBMNCs and HSB-2 which is a cell line susceptible to natural killer (NK) cell lysis. The low reactivity of DC-stimulated T cells against all of the targets (Ͻ10% at an E:T ratio of 40:1), with the exception of the CD34 + AML blasts from the time of diagnosis (mean of 62.2% (+FLT3L) and 51.7% (−FLT3L) at an E:T ratio of 40:1), indicates that the CTL lines generated in the presence or absence of FLT3 ligand were restricted to targets which expressed the cognate MHC and were leukemic in origin. The difference in percentage lysis of the AML CD34 + blasts using CTL lines generated either in the presence or absence of FLT3L was not significant in the five AML patients tested. In addition, the minimal killing of the HSB-2 cell line indicates that the level of MHC-unrestricted killing was low in this system. The predominance of MHC-restricted killing was further confirmed using monoclonal antibodies to either HLA class I or class II on the surface of the target cells. Figure  7b illustrates that the addition of a pan HLA-ABC antibody reduces the level of specific lysis of the AML CD34
+ blasts from the time of diagnosis, from a mean of 62% to a mean of 22% at an E:T ratio of 40:1, whilst the addition of an antibody directed against HLA-DR reduced the specific killing to a lesser degree (mean of 42% at an E:T ratio of 40:1), using CTL lines generated in the presence of FLT3L. Phenotypic analysis of the FLT3L+ CTL lines confirmed that there was a predominance of CD8 + T cells (37.5%), a significant proportion of CD4 + T cells (17.5%) and no CD56 + T cells. AML cells cultured in media alone had no capacity to stimulate a specific CTL response in vitro (data not shown) from any of the patients tested.
Phenotypic analyses of CTL lines generated in the absence of FLT3L showed a similar predominance of CD8 + T cells and there were no significant differences between the + and the −FLT3L CTL lines.
Discussion
Whilst advances have been made in the treatment of patients with AML, significant challenges still remain, including tumor cell resistance and the toxicity resulting from currently used chemotherapeutic regimens. Although intensive combination chemotherapy is capable of inducing disease remission in 60-85% of AML patients, long-term survival is achieved by less than 40% of individuals. 1 Hence, there is a great need for the development of novel therapeutic approaches which, ideally, would circumvent drug resistance and specifically target leukemic cells. One way to achieve this goal is to exploit the fact that immune effector cells, ie T lymphocytes, are involved in the control of AML as exemplified by the graft-versus-leukemia effect seen in the setting of allogeneic bone marrow transplantation. 2, 3 One of the major reasons why AML blasts are not recognised efficiently by T lymphocytes in vivo is that Ͼ70% of the blasts do not express the critical costimulatory molecules CD80, CD86 and CD40 [19] [20] [21] that are necessary to provide the second signal for T cell activation and, in the absence of such molecules, T cell anergy occurs. 9, 10, 22 Therefore, if the AML blasts could be modified to correct these deficits, then the AML cells themselves could be used to stimulate T cells in vitro. The major advantage of such an approach is the fact Leukemia that all of the putative leukemia-specific antigens would be presented by the modified AML cells and therefore the probability of generating specific CTLs would be maximized.
In this study we show that from 76% of AML patients with a variety of FAB subtypes, peripheral blood blast counts and clinical histories, PBMNCs, when cultured in GM-CSF, IL-4, TNF-alpha and FLT3 ligand can be differentiated into dendritic cells as demonstrated by cell morphology, immunophenotype and functional activity. The pleotropic cytokine FLT3 ligand was selected for use in our DC system because it has the capacity to stimulate the proliferation of AML blasts which bear the FLT3 receptor, it also promotes survival and inhibits apoptosis of AML blasts in vitro [15] [16] [17] and it has been shown to act synergistically with other cytokines, including GM-CSF, G-CSF and SCF to induce large numbers of DCs from CD34 + cells. 18, 23 As the blasts from many AML patients are CD34 positive, we postulated that FLT3 ligand would have beneficial effects in our differentiation system. From 24% of AML patients DCs could not be differentiated despite the cytokine combination used and we could find no distinguishing features either clinically or phenotypically on the native AML cells. As we anticipated, the yield of DCs generated in GM-CSF, IL-4, TNF-alpha and FLT3 ligand was significantly higher than when FLT3 ligand was omitted from the cultures. However, there was no correlation between the patient's blast count or clinical status at the time of investigation and the final DC number. The DCs generated with FLT3 ligand displayed a characteristic morphology and Ͼ80-95% of them were confirmed to derive from the leukemic clone as demonstrated by FISH analysis. As compared to freshly thawed AML cells, all of the costimulatory molecules, CD83 and CD1a were significantly upregulated in both sets of DCs, however, the addition of FLT3 ligand resulted in significantly higher expression of HLA-ABC, CD40 and CD83 as compared to DCs generated without this cytokine. Other molecules such as CD80, CD86, CD1a, CD33 and HLA-DR were expressed at a similar level in both sets of DCs. Interestingly, expression of HLA-ABC on DCs, cultured in either the presence or absence of FLT3L, was significantly reduced as compared to the native blasts and there was also a significant difference between the +FLT3L DCs and the −FLT3L DCs. The mechanism of HLA-ABC upregulation by FLT3L, on DCs differentiated from AML blasts, is presently unknown and this is an area which is currently under investigation in our laboratory. Although the addition of FLT3 ligand resulted in phenotypic differences, this was not reflected in their immunostimulatory capacity for either allogeneic or autologous T lymphocytes. In both assays, freshly thawed AML cells had a poor capacity to stimulate the proliferation of T cells, again reflecting their paucity of costimulatory molecules, whilst DCs generated either with or without FLT3 ligand were able to stimulate significant T cell proliferation. Finally, we asked the question as to whether DCs generated in the presence of FLT3 ligand could stimulate the generation of AML-specific CTLs in vitro and whether there was any difference in the cytotoxic potential of these CTL lines as compared to those generated from DCs generated in the absence of FLT3L. Using leukemic DCs as stimulators, CTLs were generated from Ͼ60% of AML patients which specifically recognized targets derived from the leukemic clone (eg AML blasts at diagnosis) but not HLAmatched or HLA-mismatched non-leukemic cells. Therefore, by culturing PB AML cells in a cytokine cocktail, which includes FLT3 ligand, the inherent defect of costimulatory molecule under-expression is corrected and AML-specific CTLs can be generated in vitro.
Leukemia
Although for the majority of acute myeloid leukemias, no AML-specific tumor antigens, capable of stimulating a specific cytotoxic T cell response have been identified, T cell responses have been described in vitro against proteinase 3 which is overexpressed in some myeloid leukemias 24 and the fusion protein PML/RAR-alpha in acute promyelocytic leukemia. 25, 26 In our study, we have no direct evidence that the antigens recognized are AML specific, however, the induction of a primary AML-directed cytotoxic immune response strongly suggests that the leukemic DCs constitutively express AML-specific antigens as do the AML target cells.
In vivo, T cell-mediated immunity, in the form of graft-versus-leukemia, is recognized as being an important predictor of treatment outcome in those patients receiving an allogeneic BMT. [27] [28] [29] [30] Additional evidence for the role of T cells in controlling the growth of AML comes from studies in which allogeneic lymphocytes have been used successfully to re-induce a hematological remission in up to 25% of AML patients (Kolb et al, EBMT Study Group 1999). The administration of donor lymphocytes, however, is not without risk with a significant proportion of patients developing serious graft-versus-host disease or bone marrow hypoplasia. 6, 7 Therefore, it has been proposed that adoptive immunotherapy with cytotoxic T lymphocytes which show a relative specificity for the leukemic cells may be an alternative method for treating relapsed or minimal residual disease.
We already know from studies by Choudhury and others that PB cells or isolated CD34+ blasts from AML patients can be differentiated in vitro into functional dendritic cells in the presence of a variety of cytokines including GM-CSF, IL-4, TNF-alpha, SCF and IL-6. 12, 14, 31, 32 In some cases, these leukemic DCs could also induce antileukemic reactivity in autologous T lymphocytes without requiring the addition of exogenous antigens. Our DC system differs in the fact that FLT3 ligand has been used to induce the generation of significantly larger numbers of leukemic DCs from PB AML cells and we anticipate that in the clinical setting, this will be an advantage. For patients with relapsed AML, post-allogeneic BMT, the window of opportunity for using adoptive immunotherapy may be narrow, therefore the timely generation and administration of AML-specific CTLs may be critical.
